ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
80 hedge funds and large institutions have $229M invested in Adaptimmune Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
36% less call options, than puts
Call options by funds: $191K | Put options by funds: $299K
46% less capital invested
Capital invested by funds: $426M → $229M (-$197M)
Holders
80
Holding in Top 10
1
Calls
$191K
Puts
$299K
Top Buyers
| 1 | +$4.67M | |
| 2 | +$3.35M | |
| 3 | +$2.6M | |
| 4 |
Renaissance Technologies
New York
|
+$1.1M |
| 5 |
Two Sigma Investments
New York
|
+$544K |
Top Sellers
| 1 | -$30M | |
| 2 | -$2.13M | |
| 3 | -$1.7M | |
| 4 |
Man Group
London,
United Kingdom
|
-$508K |
| 5 |
Millennium Management
New York
|
-$403K |